Jemperli

Dostarlimab, the active ingredient in Jemperli, is a PD‑1 inhibitor presented as a sterile solution for intravenous infusion. It is used to treat certain advanced endometrial cancers and other mismatch‑repair‑deficient solid tumours in adult patients.

GNH USA supplies Jemperli as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Jemperli is a PD‑1 inhibitor indicated for cancers that exhibit mismatch repair deficiency.

- Endometrial cancer (dMMR): improves progression‑free survival in adults with advanced disease. - Solid tumours with high microsatellite instability (MSI‑H): offers an immunotherapy option for patients with MSI‑H tumours. - Recurrent or metastatic endometrial carcinoma: provides treatment when standard therapies have failed.

Common Side Effects: - Fatigue: persistent tiredness experienced during treatment. - Nausea: mild to moderate feeling of sickness. - Diarrhoea: loose stools occurring intermittently. - Infusion‑related reactions: redness, itching, or fever during administration. - Rash: skin eruptions of varying intensity. - Hypothyroidism: reduced thyroid hormone production.

Serious or Rare Side Effects: - Immune‑mediated colitis: inflammation of the colon requiring urgent care. - Pneumonitis: lung inflammation that may cause breathing difficulties. - Hepatitis: liver inflammation with elevated enzymes. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Endocrinopathies: including adrenal insufficiency. - Myocarditis: inflammation of heart muscle, potentially life‑threatening.

Before initiating therapy, evaluate patient history and baseline labs. - Monitor for immune‑related adverse events: watch for signs of organ inflammation. - Assess thyroid function: test TSH and free T4 prior to and during treatment. - Screen for hepatitis B/C: test serology to prevent reactivation. - Avoid live vaccines: immunosuppression may increase infection risk. - Pregnancy and lactation: discuss potential risks and consider alternatives. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Dostarlimab may interact with other agents that affect immune function.

Major Interactions (Avoid): - Concurrent use of other immune checkpoint inhibitors: may amplify immune toxicity. - High‑dose systemic steroids or other strong immunosuppressants: can reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Live vaccines: increased risk of infection; schedule appropriately. - Anticoagulants: monitor for bleeding if thrombocytopenia occurs. - CYP450 substrates: generally minimal effect, but observe for unexpected changes.